Gennex Laboratories Limited

Gennex Laboratories Limited - pharma in Medak, Telangana, India. FY 2026 financials and compliance.
CIN L24230TG1990PLC011168 Incorporated 29 March 1990 ROC Hyderabad HQ Medak, Telangana, India
Active Listed Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹172.74 Cr
▲ 25.26% YoY
Computed EBITDA · FY 2026
₹30.08 Cr
▲ 11.43% YoY
Net profit · FY 2026
₹20.98 Cr
▲ 15.75% YoY
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹24.29 Cr
Issued & subscribed
Open charges
₹66 Cr
Satisfied ₹26.13 Cr
Company age
36 yrs
Est. 1990
Employees · EPFO
103
Latest available

About Gennex Laboratories Limited

Data last updated: 14 July 2026

Gennex Laboratories Limited is a public limited company based in Medak, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 29 March 1990, the company has been in operation for over 36 years.

Registered with ROC Hyderabad under CIN L24230TG1990PLC011168. Listed.

Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹24.29 Cr. Formerly known as Prudential Pharmaceuticals Limited and Pharmasia Drugs and Chemicals Private Limited. It is led by directors including Ranga Rao Pantulu Avasarala and Arihant Baid.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 133 Bollaram Jinnaram, Medak, Telangana, India – 502325.

As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹172.74 Cr, a growth of 25.26% compared to the previous year. The net worth stands at ₹232.84 Cr (up 19.66% YoY). Total assets are valued at ₹348.68 Cr (up 36.18% YoY).

The company has a workforce of approximately 103 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Gennex Laboratories. As per MCA filings, the company has open charges of ₹66 Cr and satisfied charges of ₹26.13 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gennexlab.com.

Company Details of Gennex Laboratories Limited
CIN L24230TG1990PLC011168
Registration Number 011168
Incorporation Date 29 March 1990
ROC Hyderabad
Listing Status Listed
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Arihant Baid Managing Director Ranga Rao Pantulu Avasarala Director Amudala Sreeramulu Nageswar Rao Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    gennexlab.com
  • Social Media
  • Registered Address
    133 Bollaram Jinnaram, Medak, Telangana, India – 502325
  • Industry
    Pharma, API Manufacturers
Company report
Gennex Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Gennex Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Gennex Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Gennex Laboratories Limited

Gennex Laboratories Limited has undergone 3 name changes throughout its history. The company was previously known as Prudential Pharmaceuticals Limited, Pharmasia Drugs And Chemicals Private Limited, and Pharmasia Drugs And Chemicals Limited. The current legal name is Gennex Laboratories Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Gennex Laboratories Limited Current
Prudential Pharmaceuticals Limited Previous
Pharmasia Drugs And Chemicals Private Limited Previous
Pharmasia Drugs And Chemicals Limited Previous

CIN History of Gennex Laboratories Limited

Gennex Laboratories Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230TG1990PLC011168, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230TG1990PLC011168 Current
L24230AP1990PLC011168 Previous
L24230AP1990PTC011168 Previous

Associated Brands with Gennex Laboratories Limited

Gennex Laboratories Limited operates one associated brand: Gennex Laboratories. These brands represent Gennex Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Gennex Laboratories
APIs are manufactured, marketed, and exported by Gennex Laboratories. gennexlab.com

Competitors & Alternatives of Gennex Laboratories Limited

Brands and companies operating in the same space as Gennex Laboratories Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.

Competitor Description Location Founded
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947
Pharmaceutics International Pharmaceutics International Pharmaceutical dosage forms are manufactured by this CDMO. Hunt Valley, United States, United States 1994
Aurobindo Pharma Aurobindo Pharma Generic biocatalytic solutions are provided for pharmaceutical applications. Hyderabad, India, India 1986
Seqens Seqens Contract manufacturing services for small molecules and peptides are provided. Ecully, France, France 2003
Asymchem Asymchem APIs and peptides are developed and manufactured by Asymchem. Morrisville, United States, United States 1995
Aptuit Aptuit Contract research and development services for small molecules are offered. Greenwich, United States, United States 2004
Continuus Pharma Continuus Pharma MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development Woburn, United States, United States 2012

Business Activity of Gennex Laboratories Limited

Gennex Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Gennex Laboratories Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Gennex Laboratories Limited

Gennex Laboratories Limited is audited by R PUGALIA & COMPANY (ICAI peer reviewed, certificate valid till 2026-08-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
R PUGALIA & COMPANY (ICAI peer reviewed, certificate valid till 2026-08-31) FY 2026 Statement on impact of audit qualification

Board of Directors of Gennex Laboratories Limited

Gennex Laboratories Limited is currently managed by 6 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ranga Rao Pantulu Avasarala
Also directs: Gennex Laboratories Limited
Director 21 Dec 2020 5 Years 8 Months Current
Arihant Baid
Also directs: Gennex Laboratories Limited, Boujee Foods Llp, Prudential Holdings Pvt. Ltd. and 5 more
Managing Director 18 May 2012 14 Years 3 Months Current
Amudala Sreeramulu Nageswar Rao
Also directs: Gennex Laboratories Limited, Kmc Constructions Limited, Basel Practitioners Private Limited and 1 more
Director 21 Dec 2020 5 Years 8 Months Current
Sandeep Kumar Daga
Also directs: Prudential Sugar Corporation Limited, Gennex Laboratories Limited
Director 30 May 2025 1 Years 2 Months Current
Dilip Raj Singhvi
Also directs: Gennex Laboratories Limited, Regium Crafts Llp, Vibes Green Energy Llp and 3 more
Director 01 Oct 2024 1 Years 10 Months Current
Khushbu Kachhawa
Also directs: Gennex Laboratories Limited, Snehaa Organics Limited
Director 14 Feb 2026 0 Years 6 Months Current
View all directors

Financials of Gennex Laboratories Limited FY 2026 filings available

Gennex Laboratories Limited reported revenue of ₹172.74 Cr (up 25.26% YoY) for FY 2026.

Revenue · FY 2026
₹172.74 Cr ▲ 25.26%
Profit · FY 2026
₹20.98 Cr ▲ 15.75%
Computed EBITDA · FY 2026
₹30.08 Cr ▲ 11.43%
Revenue₹ Cr · Consolidated0100200FY 2019: ₹56 Cr55.8FY 2019FY 2020: ₹56 Cr · -0.3% YoY55.6-0.3%FY 2020FY 2021: ₹60 Cr · +7.2% YoY59.6+7.2%FY 2021FY 2022: ₹61 Cr · +2.6% YoY61.2+2.6%FY 2022FY 2023: ₹66 Cr · +7.2% YoY65.6+7.2%FY 2023FY 2024: ₹87 Cr · +32.2% YoY86.7+32.2%FY 2024FY 2025: ₹138 Cr · +59% YoY138+59%FY 2025FY 2026: ₹173 Cr · +25.3% YoY173+25.3%FY 2026
Net Profit₹ Cr · Consolidated0102030FY 2019: ₹2 Cr2.1FY 2019FY 2020: ₹2 Cr · -13.3% YoY1.9-13.3%FY 2020FY 2021: ₹4 Cr · +117.5% YoY4+117.5%FY 2021FY 2022: ₹4 Cr · -2.8% YoY3.9-2.8%FY 2022FY 2023: ₹5 Cr · +25.4% YoY4.9+25.4%FY 2023FY 2024: ₹13 Cr · +167.7% YoY13.2+167.7%FY 2024FY 2025: ₹18 Cr · +37.6% YoY18.1+37.6%FY 2025FY 2026: ₹21 Cr · +15.7% YoY21+15.7%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0255075Q1'25: ₹28 Cr28.3Q1'25Q2'25: ₹32 Cr31.5Q2'25Q3'25: ₹38 Cr37.7Q3'25Q4'25: ₹40 Cr40.3Q4'25Q1'26: ₹34 Cr · +20.7% YoY34.2+20.7%Q1'26Q2'26: ₹37 Cr · +18% YoY37.2+18%Q2'26Q3'26: ₹40 Cr · +7.1% YoY40.4+7.1%Q3'26Q4'26: ₹61 Cr · +51.2% YoY61+51.2%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹172.74 Cr ₹137.9 Cr ₹86.71 Cr ₹65.6 Cr ₹61.21 Cr ₹59.65 Cr ₹55.62 Cr ₹55.8 Cr
Other Income ₹8.25 Cr ₹10.43 Cr ₹4.91 Cr ₹3.95 Cr ₹1.38 Cr ₹52.44 Lakh ₹95.14 Lakh ₹78.25 Lakh
Total Income ₹180.99 Cr ₹148.33 Cr ₹91.62 Cr ₹69.56 Cr ₹62.6 Cr ₹60.17 Cr ₹56.57 Cr ₹56.59 Cr
Cost of Materials Consumed ₹139.62 Cr ₹100.59 Cr ₹57.88 Cr ₹46.91 Cr ₹40.01 Cr ₹34.19 Cr ₹35.13 Cr ₹34.68 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹40.52 Lakh
Changes in Inventories -₹11.09 Cr -₹3.51 Cr -₹9.03 Cr -₹7 Cr -₹1.91 Cr ₹1.53 Cr -₹1.51 Cr -₹2.39 Cr
Employee Benefit Expense ₹8.04 Cr ₹8.35 Cr ₹7.79 Cr ₹7.87 Cr ₹6.97 Cr ₹7.21 Cr ₹6.81 Cr ₹6.12 Cr
Finance Costs ₹4.2 Cr ₹3.61 Cr ₹3.08 Cr ₹1.35 Cr ₹87.74 Lakh ₹74.35 Lakh ₹75.36 Lakh ₹79.38 Lakh
Depreciation & Amortisation ₹2.65 Cr ₹1.99 Cr ₹2.37 Cr ₹91.94 Lakh ₹78.85 Lakh ₹88.07 Lakh ₹1.01 Cr ₹98.47 Lakh
Other Expenses ₹14.34 Cr ₹15.9 Cr ₹13.04 Cr ₹13.12 Cr ₹10.76 Cr ₹10.19 Cr ₹11.94 Cr ₹12.96 Cr
Total Expenses ₹157.75 Cr ₹126.93 Cr ₹75.13 Cr ₹63.18 Cr ₹57.5 Cr ₹54.74 Cr ₹54.13 Cr ₹53.56 Cr
Profit Before Exceptional Items & Tax ₹23.24 Cr ₹21.4 Cr ₹16.49 Cr ₹6.37 Cr ₹5.09 Cr ₹5.43 Cr ₹2.44 Cr ₹3.03 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 -₹37.13 Lakh ₹10.86 Lakh ₹0
Profit Before Tax ₹23.24 Cr ₹21.4 Cr ₹16.49 Cr ₹6.37 Cr ₹5.09 Cr ₹5.06 Cr ₹2.55 Cr ₹3.03 Cr
Total Tax Expense ₹2.26 Cr ₹3.27 Cr ₹3.32 Cr ₹1.45 Cr ₹1.17 Cr ₹1.02 Cr ₹69.23 Lakh ₹80.64 Lakh
Net Profit ₹20.98 Cr ₹18.12 Cr ₹13.18 Cr ₹4.92 Cr ₹3.92 Cr ₹4.04 Cr ₹1.86 Cr ₹2.14 Cr
  attributable to Owners ₹18.51 Cr - - - - - ₹0 ₹0
  attributable to NCI ₹2.52 Cr - - - - - ₹0 ₹0
Other Comprehensive Income ₹5.19 Lakh ₹0 -₹1.8 Cr ₹1.27 Cr ₹18.23 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income ₹21.03 Cr ₹18.12 Cr ₹11.37 Cr ₹6.19 Cr ₹4.11 Cr ₹4.04 Cr ₹1.86 Cr ₹2.14 Cr
EBITDA (computed) ₹30.08 Cr ₹27 Cr ₹21.94 Cr ₹8.65 Cr ₹6.76 Cr ₹7.06 Cr ₹4.2 Cr ₹4.81 Cr
Basic EPS ₹0.76 ₹0.79 ₹0.67 ₹0.35 ₹0.33 ₹0.32 ₹0.15 ₹0.17
Diluted EPS ₹0.76 ₹0.78 ₹0.61 ₹0.35 ₹0.33 ₹0.32 ₹0.15 ₹0.17
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹348.68 Cr ₹256.04 Cr ₹229.99 Cr ₹132.32 Cr ₹68.03 Cr ₹58.9 Cr ₹56.94 Cr ₹51.82 Cr
Non-current Assets ₹84.02 Cr ₹74.91 Cr ₹68.17 Cr ₹83.63 Cr ₹20.84 Cr ₹21.23 Cr ₹21.98 Cr ₹22.78 Cr
Current Assets ₹264.66 Cr ₹181.13 Cr ₹161.81 Cr ₹48.68 Cr ₹47.18 Cr ₹37.67 Cr ₹34.97 Cr ₹29.04 Cr
Property, Plant & Equipment ₹57.8 Cr ₹56.61 Cr ₹52.7 Cr ₹67.63 Cr ₹13.7 Cr ₹14.13 Cr ₹14.93 Cr ₹15.64 Cr
Inventories ₹53.89 Cr ₹35.94 Cr ₹25.17 Cr ₹15.69 Cr ₹7.74 Cr ₹5.02 Cr ₹7.44 Cr ₹5.33 Cr
Trade Receivables ₹43.56 Cr ₹14.16 Cr ₹17.81 Cr ₹9.42 Cr ₹11.31 Cr ₹8.95 Cr ₹6.28 Cr ₹10.4 Cr
Cash & Equivalents ₹5.79 Lakh ₹55.28 Lakh ₹47.86 Lakh ₹56.29 Lakh ₹32.12 Lakh ₹18.61 Lakh ₹19.37 Lakh ₹19.51 Lakh
Equity (Net Worth) ₹232.84 Cr ₹194.59 Cr ₹176.46 Cr ₹86.52 Cr ₹43.82 Cr ₹39.71 Cr ₹35.67 Cr ₹33.91 Cr
Equity Share Capital ₹24.29 Cr ₹22.74 Cr ₹22.74 Cr ₹18.02 Cr ₹12.65 Cr ₹12.65 Cr ₹12.65 Cr ₹12.65 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹35.95 Cr ₹10.22 Cr ₹5.72 Cr ₹1.05 Cr ₹10.12 Cr ₹7.36 Cr ₹4.98 Cr ₹4.54 Cr
Total Debt (computed) ₹35.95 Cr ₹10.22 Cr ₹5.72 Cr ₹1.05 Cr ₹10.12 Cr ₹7.36 Cr ₹4.98 Cr ₹4.54 Cr
Current Liabilities ₹72.4 Cr ₹44.55 Cr ₹40.3 Cr ₹29.51 Cr ₹24.21 Cr ₹19.04 Cr ₹20.86 Cr ₹17.3 Cr
Total Liabilities ₹115.84 Cr ₹61.45 Cr ₹53.52 Cr ₹45.8 Cr ₹24.21 Cr ₹19.19 Cr ₹21.27 Cr ₹17.92 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹63.65 Cr -₹10.8 Cr -₹46.69 Cr ₹23.72 Cr ₹6.64 Cr
Investing Cash Flow -₹4.8 Cr ₹82.37 Lakh ₹18.91 Cr -₹38.37 Cr -₹1.26 Cr
Financing Cash Flow ₹65.3 Cr ₹4.57 Cr ₹73.68 Cr ₹21.03 Cr ₹1.87 Cr
Capital Expenditure ₹11.94 Cr ₹8.95 Cr ₹0 ₹39.79 Cr ₹38.97 Lakh
Free Cash Flow (computed) -₹75.59 Cr -₹19.74 Cr -₹46.69 Cr -₹16.07 Cr ₹6.25 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹3.15 Cr -₹5.41 Cr ₹45.91 Cr ₹6.38 Cr ₹7.24 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹60.96 Cr ₹40.37 Cr ₹37.24 Cr ₹34.18 Cr ₹40.33 Cr ₹37.71 Cr ₹31.55 Cr ₹28.32 Cr
Other Income ₹1.32 Cr ₹2.59 Cr ₹2.06 Cr ₹2.28 Cr ₹3.83 Cr ₹2.3 Cr ₹1.83 Cr ₹2.46 Cr
Total Income ₹62.27 Cr ₹42.96 Cr ₹39.3 Cr ₹36.45 Cr ₹44.16 Cr ₹40.01 Cr ₹33.38 Cr ₹30.79 Cr
Cost of Materials Consumed ₹55.29 Cr ₹29.96 Cr ₹30.56 Cr ₹23.82 Cr ₹33.06 Cr ₹28.62 Cr ₹20.89 Cr ₹18.02 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹2.67 Cr -₹1.66 Cr -₹5.15 Cr -₹1.62 Cr -₹76.05 Lakh -₹94.45 Lakh -₹1.58 Cr -₹22.28 Lakh
Employee Benefit Expense ₹1.17 Cr ₹2.34 Cr ₹1.84 Cr ₹2.69 Cr ₹2.08 Cr ₹2.06 Cr ₹1.92 Cr ₹2.29 Cr
Finance Costs ₹1.08 Cr ₹1.11 Cr ₹1.03 Cr ₹97.9 Lakh ₹1.2 Cr ₹84.07 Lakh ₹1.11 Cr ₹73.17 Lakh
Depreciation & Amortisation ₹1.16 Cr ₹51.85 Lakh ₹46.5 Lakh ₹50.4 Lakh ₹54.32 Lakh ₹49.73 Lakh ₹21.86 Lakh ₹45.29 Lakh
Other Expenses ₹1.58 Cr ₹3.75 Cr ₹4.5 Cr ₹4.22 Cr ₹4.09 Cr ₹3.11 Cr ₹4.7 Cr ₹4 Cr
Total Expenses ₹57.61 Cr ₹36.01 Cr ₹33.24 Cr ₹30.59 Cr ₹40.21 Cr ₹34.19 Cr ₹27.26 Cr ₹25.28 Cr
Profit Before Exceptional Items & Tax ₹4.67 Cr ₹6.94 Cr ₹6.06 Cr ₹5.87 Cr ₹3.95 Cr ₹5.82 Cr ₹6.12 Cr ₹5.51 Cr
Exceptional Items ₹0 -₹30 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹4.67 Cr ₹6.64 Cr ₹6.06 Cr ₹5.87 Cr ₹3.95 Cr ₹5.82 Cr ₹6.12 Cr ₹5.51 Cr
Total Tax Expense ₹20.89 Lakh ₹65 Lakh ₹55 Lakh ₹85 Lakh ₹88.47 Lakh ₹75 Lakh ₹75 Lakh ₹85 Lakh
Net Profit ₹4.46 Cr ₹5.99 Cr ₹5.51 Cr ₹5.02 Cr ₹3.07 Cr ₹5.07 Cr ₹5.37 Cr ₹4.66 Cr
  attributable to Owners ₹3.79 Cr ₹5.24 Cr ₹5.03 Cr ₹4.59 Cr - ₹4.64 Cr ₹4.83 Cr ₹0
  attributable to NCI ₹72.03 Lakh ₹75.51 Lakh ₹47.92 Lakh ₹42.48 Lakh - ₹42.14 Lakh ₹54.52 Lakh ₹0
Other Comprehensive Income ₹5.19 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹4.51 Cr ₹5.99 Cr ₹5.51 Cr ₹5.02 Cr ₹3.07 Cr ₹5.07 Cr ₹5.37 Cr ₹4.66 Cr
EBITDA (computed) ₹6.9 Cr ₹8.57 Cr ₹7.56 Cr ₹7.35 Cr ₹5.7 Cr ₹7.15 Cr ₹7.45 Cr ₹6.69 Cr
Basic EPS ₹0.16 ₹0.22 ₹0.21 ₹0.22 ₹0.13 ₹0.22 ₹0.21 ₹0.21
Diluted EPS ₹0.16 ₹0.22 ₹0.21 ₹0.21 ₹0.13 ₹0.22 ₹0.21 ₹0.21
Latest 8 quarters shown.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2019
Revenue from Operations ₹119.86 Cr ₹94.58 Cr ₹66.8 Cr ₹65.1 Cr ₹61.21 Cr ₹59.65 Cr ₹55.8 Cr
Other Income ₹8.14 Cr ₹9.22 Cr ₹4.3 Cr ₹3.4 Cr ₹1.38 Cr ₹52.44 Lakh ₹78.25 Lakh
Total Income ₹128 Cr ₹103.8 Cr ₹71.1 Cr ₹68.5 Cr ₹62.6 Cr ₹60.17 Cr ₹56.59 Cr
Cost of Materials Consumed ₹96.83 Cr ₹67.18 Cr ₹40.88 Cr ₹46.91 Cr ₹40.01 Cr ₹34.19 Cr ₹34.68 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹40.52 Lakh
Changes in Inventories -₹9.29 Cr -₹70.14 Lakh -₹2.44 Cr -₹7 Cr -₹1.91 Cr ₹1.53 Cr -₹2.39 Cr
Employee Benefit Expense ₹6.67 Cr ₹6.43 Cr ₹6.05 Cr ₹7.71 Cr ₹6.97 Cr ₹7.21 Cr ₹6.12 Cr
Finance Costs ₹2.47 Cr ₹1.58 Cr ₹1.16 Cr ₹1.23 Cr ₹87.74 Lakh ₹74.35 Lakh ₹79.38 Lakh
Depreciation & Amortisation ₹96.76 Lakh ₹76.95 Lakh ₹81.04 Lakh ₹74.44 Lakh ₹78.85 Lakh ₹88.07 Lakh ₹98.47 Lakh
Other Expenses ₹12.12 Cr ₹11.48 Cr ₹9.89 Cr ₹12.89 Cr ₹10.76 Cr ₹10.19 Cr ₹12.96 Cr
Total Expenses ₹109.76 Cr ₹86.74 Cr ₹56.35 Cr ₹62.49 Cr ₹57.5 Cr ₹54.74 Cr ₹53.56 Cr
Profit Before Exceptional Items & Tax ₹18.24 Cr ₹17.06 Cr ₹14.75 Cr ₹6.01 Cr ₹5.09 Cr ₹5.43 Cr ₹3.03 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 -₹37.13 Lakh ₹0
Profit Before Tax ₹18.24 Cr ₹17.06 Cr ₹14.75 Cr ₹6.01 Cr ₹5.09 Cr ₹5.06 Cr ₹3.03 Cr
Total Tax Expense ₹2.11 Cr ₹3.02 Cr ₹2.96 Cr ₹1.45 Cr ₹1.17 Cr ₹1.02 Cr ₹80.64 Lakh
Net Profit ₹16.13 Cr ₹14.04 Cr ₹11.8 Cr ₹4.56 Cr ₹3.92 Cr ₹4.04 Cr ₹2.22 Cr
Other Comprehensive Income ₹5.19 Lakh ₹0 ₹11.06 Lakh ₹2.36 Lakh ₹18.23 Lakh ₹0 ₹0
Total Comprehensive Income ₹16.18 Cr ₹14.04 Cr ₹11.91 Cr ₹4.58 Cr ₹4.11 Cr ₹4.04 Cr ₹2.22 Cr
EBITDA (computed) ₹21.67 Cr ₹19.42 Cr ₹16.72 Cr ₹7.99 Cr ₹6.76 Cr ₹7.06 Cr ₹4.81 Cr
Basic EPS ₹0.67 ₹0.62 ₹0.70 ₹0.26 ₹0.33 ₹0.32 ₹0.18
Diluted EPS ₹0.67 ₹0.61 ₹0.64 ₹0.26 ₹0.33 ₹0.32 ₹0.18
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2019
Total Assets ₹273.82 Cr ₹218.38 Cr ₹205.34 Cr ₹96.22 Cr ₹68.21 Cr ₹59.08 Cr ₹51.91 Cr
Non-current Assets ₹35.73 Cr ₹31.36 Cr ₹26.35 Cr ₹24.06 Cr ₹21.03 Cr ₹21.42 Cr ₹22.87 Cr
Current Assets ₹238.09 Cr ₹187.02 Cr ₹178.99 Cr ₹72.16 Cr ₹47.18 Cr ₹37.67 Cr ₹29.04 Cr
Property, Plant & Equipment ₹21.64 Cr ₹19.65 Cr ₹15.83 Cr ₹15.18 Cr ₹13.7 Cr ₹14.13 Cr ₹15.64 Cr
Inventories ₹41.63 Cr ₹24.59 Cr ₹16.07 Cr ₹14.97 Cr ₹7.74 Cr ₹5.02 Cr ₹5.33 Cr
Trade Receivables ₹33.37 Cr ₹11.89 Cr ₹13.57 Cr ₹8.82 Cr ₹11.31 Cr ₹8.95 Cr ₹10.4 Cr
Cash & Equivalents ₹5.26 Lakh ₹54.95 Lakh ₹47.71 Lakh ₹42.02 Lakh ₹32.12 Lakh ₹18.61 Lakh ₹19.51 Lakh
Equity (Net Worth) ₹218.12 Cr ₹184.8 Cr ₹170.76 Cr ₹79.02 Cr ₹44 Cr ₹39.89 Cr ₹34 Cr
Equity Share Capital ₹24.29 Cr ₹22.74 Cr ₹22.74 Cr ₹18.02 Cr ₹12.65 Cr ₹12.65 Cr ₹12.65 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹22.82 Cr ₹1.24 Cr ₹84.72 Lakh ₹98.16 Lakh ₹10.12 Cr ₹7.36 Cr ₹4.54 Cr
Total Debt (computed) ₹22.82 Cr ₹1.24 Cr ₹84.72 Lakh ₹98.16 Lakh ₹10.12 Cr ₹7.36 Cr ₹4.54 Cr
Current Liabilities ₹52.08 Cr ₹29.11 Cr ₹32.82 Cr ₹15.91 Cr ₹24.21 Cr ₹19.04 Cr ₹17.3 Cr
Total Liabilities ₹55.7 Cr ₹33.59 Cr ₹34.58 Cr ₹17.2 Cr ₹24.21 Cr ₹19.19 Cr ₹17.92 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹40.18 Cr -₹9.56 Cr -₹33.43 Cr -₹14.45 Cr ₹6.64 Cr
Investing Cash Flow ₹1.62 Cr ₹2.63 Cr ₹92.72 Lakh -₹76.51 Lakh -₹1.26 Cr
Financing Cash Flow ₹35.4 Cr ₹1.53 Cr ₹79.01 Cr ₹21.35 Cr ₹1.87 Cr
Capital Expenditure ₹5.51 Cr ₹5.96 Cr ₹2.84 Cr ₹2.22 Cr ₹38.97 Lakh
Free Cash Flow (computed) -₹45.7 Cr -₹15.52 Cr -₹36.27 Cr -₹16.67 Cr ₹6.25 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹3.16 Cr -₹5.4 Cr ₹46.51 Cr ₹6.14 Cr ₹7.24 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹36.71 Cr ₹28.18 Cr ₹29.33 Cr ₹25.64 Cr ₹23.28 Cr ₹25.28 Cr ₹24.69 Cr ₹21.33 Cr
Other Income ₹1.3 Cr ₹2.54 Cr ₹2.04 Cr ₹2.26 Cr ₹2.87 Cr ₹2.07 Cr ₹1.82 Cr ₹2.46 Cr
Total Income ₹38.01 Cr ₹30.71 Cr ₹31.37 Cr ₹27.9 Cr ₹26.15 Cr ₹27.35 Cr ₹26.51 Cr ₹23.79 Cr
Cost of Materials Consumed ₹33.84 Cr ₹18.15 Cr ₹26.57 Cr ₹18.27 Cr ₹21.45 Cr ₹20.66 Cr ₹13.89 Cr ₹11.19 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹2.53 Cr ₹1.16 Cr -₹6.94 Cr -₹98.8 Lakh -₹2.81 Cr -₹2.19 Cr ₹2.16 Cr ₹2.13 Cr
Employee Benefit Expense ₹82.82 Lakh ₹2.09 Cr ₹1.88 Cr ₹1.88 Cr ₹1.89 Cr ₹1.14 Cr ₹1.49 Cr ₹1.9 Cr
Finance Costs ₹63.11 Lakh ₹68.98 Lakh ₹55.45 Lakh ₹59.15 Lakh ₹53.49 Lakh ₹40.82 Lakh ₹46.97 Lakh ₹29.49 Lakh
Depreciation & Amortisation ₹34.94 Lakh ₹21.25 Lakh ₹20.7 Lakh ₹19.87 Lakh ₹22.59 Lakh ₹19.67 Lakh ₹5.21 Lakh ₹17.18 Lakh
Other Expenses ₹1.69 Cr ₹3.15 Cr ₹3.87 Cr ₹3.1 Cr ₹2.68 Cr ₹2.17 Cr ₹3.44 Cr ₹3.19 Cr
Total Expenses ₹34.81 Cr ₹25.46 Cr ₹26.13 Cr ₹23.05 Cr ₹23.97 Cr ₹22.39 Cr ₹21.5 Cr ₹18.88 Cr
Profit Before Exceptional Items & Tax ₹3.2 Cr ₹5.25 Cr ₹5.23 Cr ₹4.85 Cr ₹2.18 Cr ₹4.96 Cr ₹5.01 Cr ₹4.92 Cr
Exceptional Items ₹0 -₹30 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.2 Cr ₹4.95 Cr ₹5.23 Cr ₹4.85 Cr ₹2.18 Cr ₹4.96 Cr ₹5.01 Cr ₹4.92 Cr
Total Tax Expense ₹20.89 Lakh ₹50 Lakh ₹70 Lakh ₹70 Lakh ₹67.47 Lakh ₹75 Lakh ₹85 Lakh ₹75 Lakh
Net Profit ₹2.99 Cr ₹4.45 Cr ₹4.53 Cr ₹4.15 Cr ₹1.5 Cr ₹4.21 Cr ₹4.16 Cr ₹4.17 Cr
Other Comprehensive Income ₹5.19 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹3.05 Cr ₹4.45 Cr ₹4.53 Cr ₹4.15 Cr ₹1.5 Cr ₹4.21 Cr ₹4.16 Cr ₹4.17 Cr
EBITDA (computed) ₹4.18 Cr ₹6.15 Cr ₹5.99 Cr ₹5.64 Cr ₹2.94 Cr ₹5.56 Cr ₹5.53 Cr ₹5.38 Cr
Basic EPS ₹0.13 ₹0.18 ₹0.19 ₹0.18 ₹0.06 ₹0.19 ₹0.18 ₹0.18
Diluted EPS ₹0.13 ₹0.18 ₹0.19 ₹0.17 ₹0.06 ₹0.19 ₹0.18 ₹0.18
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Gennex Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Gennex Laboratories Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 23.63%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 76.37% of Gennex Laboratories Limited. The company had 84,133 shareholders on record.

Promoters: 23.63%Retail & Others: 76.37%
Mar 2026
QUARTER
23.63% Promoters
76.37% Retail & Others
Promoter holding - history
Now 23.63% · Mar 2026High 23.63% · Mar 2026Low 18.42% · Mar 2024
17%19%21%23%25%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 23.38%Sep 2023: 23.60%Dec 2023: 23.60%Mar 2024: 18.42%Jun 2024: 18.42%Sep 2024: 18.42%Dec 2024: 18.42%Mar 2025: 18.42%Jun 2025: 19.83%Sep 2025: 23.62%Dec 2025: 23.62%Mar 2026: 23.63%18.42%23.63%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters23.63%23.62%23.62%19.83%18.42%18.42%
Public76.37%76.38%76.38%80.17%81.58%81.58%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters23.63%18.42%18.42%
Public76.37%81.58%81.58%
Promoter change (YoY, %pts)+5.21+0.00-

Group Structure of Gennex Laboratories Limited

Gennex Laboratories Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Gennex Laboratories Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Deccan Remedies Limited U72200TG1994PLC016962 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Gennex Laboratories Limited

Open charges
₹66 Cr
Satisfied charges
₹26.13 Cr
Breakdown by lending institutions
Others₹65.71 Cr
Hdfc Bank Limited₹0.25 Cr
Axis Bank Limited₹0.04 Cr
Latest charge details
DateLenderAmountStatus
17 Jan 2026 Hdfc Bank Limited ₹25 Lakh Open
24 Sep 2025 Others ₹1.5 Cr Open
22 Nov 2024 Others ₹6.65 Cr Open
01 Oct 2024 Others ₹5 Cr Open
31 Oct 2023 Others ₹22.5 Lakh Open

Total charge records: 12 View all charges

Employees and EPFO Compliance at Gennex Laboratories Limited

Gennex Laboratories Limited has a workforce of 103 employees as of Mar 30, 2024.

Employee count
103
Active EPFO establishments
1
Employee growth
5.1%
Premium access

Employee and EPFO history for Gennex Laboratories Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Gennex Laboratories Limited

Premium access

GST registrations and filing compliance for Gennex Laboratories Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Gennex Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Gennex Laboratories Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Gennex Laboratories Limited

Premium access

MSME payment history for Gennex Laboratories Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Gennex Laboratories Limited

Premium access

Corporate group structure for Gennex Laboratories Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Gennex Laboratories Limited

Premium access

MCA filings and documents for Gennex Laboratories Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Gennex Laboratories Limited

Directors
14 Feb 2026
Khushbu Kachhawa was appointed as a Director on 14 Feb 2026 & has been associated with this company since 6 months 7 days.
Charges
17 Jan 2026
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 101264561 was registered on 17 Jan 2026.
Activity
30 Sep 2025
Gennex Laboratories Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
24 Sep 2025
A charge with Others amounted to Rs. 1.50 Cr with Charge ID 101170708 was registered on 24 Sep 2025.
Charges
24 Sep 2025
A charge with Others of Rs. 30.00 Cr registered on 07 Feb 2023 with Charge ID 100693118 was modified on 24 Sep 2025.
Directors
30 May 2025
Sandeep Kumar Daga was appointed as a Director on 30 May 2025 & has been associated with this company since 1 year 2 months.

Recent News on Gennex Laboratories Limited

Big Boy Toyz launches clothing line
27 Aug 2017 · Indiatimes

Frequently Asked Questions about Gennex Laboratories Limited

Gennex Laboratories Limited is an active public limited company in the pharma sector based in Medak, Telangana, India. It was incorporated on 29 March 1990 (36+ years old) and is registered under CIN L24230TG1990PLC011168. The company has 103 employees.

Gennex Laboratories Limited reported revenue of ₹172.74 Cr for FY 2026 (up 25.26% YoY) based on consolidated BSE filings.

The current directors of Gennex Laboratories Limited are:

The primary industry of Gennex Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes, Gennex Laboratories Limited is a listed company.

Gennex Laboratories Limited can be reached at the registered office: 133 Bollaram Jinnaram, Medak, Telangana, India – 502325, or through the website gennexlab.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available